7 results
PRE 14A
GLTO
Galecto Inc
16 Apr 24
Preliminary proxy
4:00pm
includes one director who identifies as women, and three directors who identify as a racial or ethnic minority.
The Nominating and Corporate Governance
424B4
GLTO
Galecto Inc
30 Oct 20
Prospectus supplement with pricing info
4:31pm
is already the leading cause of liver transplantation in women.
Our solution – GB1211
We have demonstrated activity of GB1211 in preclinical models
S-1/A
GLTO
Galecto Inc
22 Oct 20
IPO registration (amended)
6:13am
it is growing more rapidly, NASH is expected eventually to become the primary cause. NASH is already the leading cause of liver transplantation in women.
Our
S-1
edt iin05rmv7
7 Oct 20
IPO registration
5:01pm
DRS
8sotr
2 Sep 20
Draft registration statement
12:00am
- Prev
- 1
- Next